{
    "medicine_id": "c09594328dc9d9fdc594830adeaa4dbd2f0400fd",
    "platform_id": "DB12872",
    "metadata": {
        "name": "Vonvendi 650 unit Powder for solution",
        "composition": "650 unit Vonicog Alfa",
        "clinical_particulars": {
            "therapeutic_indications": "Vonicog alfa is indicated for the on demand treatment and control of bleeding episodes in adults previously diagnosed with von Willebrand disease L1866 Vonicog alfa contains only the vWF and thus its administration offers the flexibility to administer the coagulation factor VIII if needed The von Willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von Willebrand factor vWF Due to this deficiency the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding There are three types of this disease and type 3 is an autosomal recessive inherited disorder marked by very low or absent levels of vWF L1867",
            "contraindications": {
                "disease": "Studies performed in vitro and in vivo have indicated no mutagenic potential Carcinogenic or fertility studies have not been performed L1866",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Vonicog alfa does not present a risk of transmission of blood borne pathogens as it is a recombinant plasma and albumin free protein The two first clinical trials showed an effective reduction of bleeding episodes in different sites of the body This effect was observed even after the first infusion in 81 of the cases A32262",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}